SCHEMBL6499804

SCHEMBL6499804

Nc1cccc(-c2ccc(C(=O)NC3CC4CC3CN4)o2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
MAPT P10636 4/20 0.44
KDM4E B2RXH2 3/20 0.44
L3MBTL1 Q9Y468 3/20 0.44
GAA P10253 2/20 0.44
RAB9A P51151 5/20 0.41
NPC1 O15118 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
LMNA P02545 1/20 0.41
S1PR4 O95977 1/20 0.36
POLB P06746 1/20 0.36
C3AR1 Q16581 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
HPGD P15428 2/20 0.36
MEN1 O00255 1/20 0.36
PRKD3 O94806 1/20 0.36
KMT2A Q03164 1/20 0.36
PRKD1 Q15139 1/20 0.36
PRKD2 Q9BZL6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498034 0.88 RAB9A (0.42) ALDH1A1MAPTKDM4EL3MBTL1GAA
SCHEMBL6486556 0.88 ALDH1A1 (0.42) ALDH1A1MAPTKDM4EL3MBTL1GAA
SCHEMBL6491662 0.87 ALDH1A1 (0.55) ALDH1A1MAPTKDM4EL3MBTL1GAA
SCHEMBL6496112 0.87 SLC9A1 (0.46) ALDH1A1MAPTKDM4EL3MBTL1GAA
SCHEMBL6488068 0.87 NR4A1 (0.51) ALDH1A1MAPTKDM4EL3MBTL1GAA
SCHEMBL6489856 0.87 ERCC5 (0.45) ALDH1A1MAPTKDM4EL3MBTL1GAA
SCHEMBL6486913 0.86 SLC9A1 (0.48) ALDH1A1MAPTKDM4ERAB9ANPC1
SCHEMBL6488949 0.84 NQO2 (0.51) ALDH1A1MAPTKDM4ERAB9ANPC1
SCHEMBL6491489 0.82 FAAH (0.48) AXLMERTK
SCHEMBL6485912 0.82 ALDH1A1 (0.43) ALDH1A1MAPTKDM4EL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
EP-1442041-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-08-04 EP claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
WO-2003040147-A1 AZABICYCLIC-SUBSTITUTED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE__________________________________________________________________________________________________________________________ PHARMACIA & UPJOHN COMPANY (US) 2003-05-15 WO claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 ALDH1A1 625/4885MAPT 4385/4885KDM4E 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.